We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
+22.79%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$359M
AUM Growth
+$110M
Cap. Flow
+$97.8M
Cap. Flow %
27.21%
Top 10 Hldgs %
61.96%
Holding
53
New
19
Increased
12
Reduced
12
Closed
9

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$20.1M
2
BBIO icon
BridgeBio Pharma
BBIO
+$20M
3
CYTK icon
Cytokinetics
CYTK
+$18.9M
4
GH icon
Guardant Health
GH
+$10.1M
5
KIDS icon
OrthoPediatrics
KIDS
+$9.04M

Top Sells

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$14.5M
2
QDEL icon
QuidelOrtho
QDEL
+$8.76M
3
PCRX icon
Pacira BioSciences
PCRX
+$5.04M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.68M
5
NUVB icon
Nuvation Bio
NUVB
+$3.46M

Sector Composition

Rank Sector Weight
1 Healthcare 96.72%
2 Industrials 3.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STTK icon
1
Shattuck Labs
STTK
$710M
$33.3M 9.26%
3,725,000
+942,203
+34% +$8.63M
ADCT icon
2
ADC Therapeutics
ADCT
$146M
$31.7M 8.81%
7,050,300
+578,500
+9% +$2.13M
LKFT
3
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$30M 8.34%
931,512
+104,218
+13% +$3.88M
MGTX icon
4
MeiraGTx Holdings
MGTX
$1.09B
$24.4M 6.78%
4,017,301
-33,413
-0.8% -$211K
KURA icon
5
Kura Oncology
KURA
$922M
$20.5M 5.7%
960,000
+10,000
+1% +$194K
ROIV icon
6
Roivant Sciences
ROIV
$25.2B
$19.6M 5.45%
+1,860,000
New +$20.1M
BBIO icon
7
BridgeBio Pharma
BBIO
$16.5B
$18.2M 5.07%
+589,530
New +$20M
CYTK icon
8
Cytokinetics
CYTK
$11B
$17.2M 4.78%
+245,000
New +$18.9M
MDT icon
9
Medtronic
MDT
$107B
$15.7M 4.36%
180,000
-40,000
-18% -$3.41M
KIDS icon
10
OrthoPediatrics
KIDS
$485M
$12.2M 3.39%
418,261
+323,261
+340% +$9.04M
MIRM icon
11
Mirum Pharmaceuticals
MIRM
$6.89B
$11.7M 3.25%
465,000
+171,699
+59% +$4.72M
GH icon
12
Guardant Health
GH
$19.5B
$9.7M 2.7%
+470,000
New +$10.1M
KELYA icon
13
Kelly Services Class A
KELYA
$526M
$8.73M 2.43%
+348,686
New +$7.82M
ABCL icon
14
AbCellera Biologics
ABCL
$1.62B
$8.11M 2.26%
1,790,000
+90,000
+5% +$459K
ERAS icon
15
Erasca
ERAS
$6.63B
$7.54M 2.1%
3,659,755
+3,060,297
+511% +$6.12M
BCRX icon
16
BioCryst Pharmaceuticals
BCRX
$2.37B
$7.11M 1.98%
1,400,000
-832,242
-37% -$4.68M
IMVT icon
17
Immunovant
IMVT
$8.09B
$6.3M 1.75%
+195,000
New +$7.11M
PFE icon
18
Pfizer
PFE
$140B
$5.97M 1.66%
+215,000
New +$5.97M
ALKS icon
19
Alkermes
ALKS
$8.82B
$5.82M 1.62%
215,000
+200,000
+1,333% +$5.68M
UHS icon
20
Universal Health Services
UHS
$9.43B
$5.47M 1.52%
30,000
+1,910
+7% +$315K
MRVI icon
21
Maravai LifeSciences
MRVI
$997M
$5.2M 1.45%
+599,460
New +$4.06M
ZYME icon
22
Zymeworks
ZYME
$1.68B
$4.32M 1.2%
+410,948
New +$4.56M
PRTA icon
23
Prothena Corp
PRTA
$458M
$4.22M 1.17%
170,469
-59,070
-26% -$1.76M
NBIX icon
24
Neurocrine Biosciences
NBIX
$17.7B
$4.21M 1.17%
30,500
-5,400
-15% -$737K
CRBP icon
25
Corbus Pharmaceuticals
CRBP
$170M
$3.95M 1.1%
+100,617
New +$2.48M
1
2 3

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q1 2024 Portfolio in Review

As of Q1 2024, Prosight Management held 53 positions worth $359M, up 44% from $249M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Prosight Management deployed $97.8M of net new capital in Q1 2024, opening 19 new positions and adding to 12 existing holdings. Its largest new stake was Roivant Sciences: 1,860,000 shares worth $19.6M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Pacira BioSciences, an estimated $5.04M trimmed.

  • Prosight Management's largest Q1 2024 buy was Roivant Sciences: 1,860,000 shares worth $19.6M.
  • Prosight Management added most to OrthoPediatrics in Q1 2024, an estimated $9.04M increase.
  • Prosight Management's biggest Q1 2024 reduction was Pacira BioSciences, cutting an estimated $5.04M.
  • Prosight Management fully exited Oric Pharmaceuticals in Q1 2024, selling an estimated $14.5M.
  • Prosight Management's ten largest holdings make up 62% of its $359M portfolio in Q1 2024.
  • Prosight Management opened 19 new positions and closed 9 in Q1 2024.
  • Prosight Management's portfolio value rose 44% quarter-over-quarter to $359M.

Based on Prosight Management's 13F filing for Q1 2024, filed 15 May 2024.